{"news": [{"date": "20240322100900", "headline": "Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development", "summary": "Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month."}, {"date": "20240324200400", "headline": "Wall Street\u2019s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240324223400", "headline": "If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,400 Today", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240324223904", "headline": "InvestorBrandMedia: FDA Approves Vertex Pharmaceuticals (NASDAQ", "summary": "In a significant stride toward addressing one of the most challenging inherited kidney diseases, Vertex Pharmaceuticals Incorporated has recently made headlines with its latest breakthrough in the..."}, {"date": "20240325071000", "headline": "Vertex (VRTX) Continues to Diversify Beyond CF Franchise", "summary": "While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates."}, {"date": "20240325155020", "headline": "Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts", "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day."}, {"date": "20240325203322", "headline": "Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape", "summary": "Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. See why CRSP stock is a Buy."}, {"date": "20240326020000", "headline": "Vortex Energy Closes Charity Flow-Through Private Placement for Gross Proceeds of C$830,000", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240326044400", "headline": "3 Biotech Stocks to Buy for the Next Bull Run: March 2024", "summary": "As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performance relative to the broader market. With advancements in gene editing, personalized medicine and novel therapeutics, the sector is on the cusp of delivering transformative healthcare solutions. The global biotechnology market is set for remarkable growth. It is forecast to soar from $1 trillion in 202"}, {"date": "20240326044900", "headline": "Biotech Roundtable: Is CRISPR all it's cracked up to be?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240326063800", "headline": "Vortex Energy Advances Exploration with C$830K Placement", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240326072300", "headline": "Wall Street Lunch: Florida Bans Social Media For Under 14", "summary": "Florida signs bill requiring parental consent for minors to create social media accounts and bans children under 14 from joining social media."}, {"date": "20240327214600", "headline": "Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240328041200", "headline": "May 10th Options Now Available For Vertex Pharmaceuticals (VRTX)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240328063900", "headline": "10 Health Care Stocks With Whale Alerts In Today's Session", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240328105825", "headline": "Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week \u2014 Here's Why", "summary": "Crispr stock is down for the fifth straight week as the top Cathie Wood's holding struggles amid dim expectations for its gene-editing drug."}, {"date": "20240330045000", "headline": "3 Unstoppable Stocks to Buy Hand Over Fist in April", "summary": "These stocks have exceptionally bright prospects."}, {"date": "20240331033000", "headline": "Are Investors Vastly Underestimating CRISPR Therapeutics Stock (NASDAQ:CRSP)?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240331043000", "headline": "2 Rock-Solid Growth Stocks to Buy Right Now and Hold for at Least 5 Years", "summary": "Great businesses are here to stay. These are two excellent examples."}, {"date": "20240331071500", "headline": "1 Top Growth Stock to Buy and Hold Forever", "summary": "This drugmaker looks unstoppable."}, {"date": "20240401011100", "headline": "Vertex Pharmaceuticals advances inaxaplin into Phase 3 portion of trial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240401023000", "headline": "Meet The \"Magnificent Seven\" of Healthcare Stocks", "summary": "The tech sector doesn't have a monopoly on magnificent corporations."}, {"date": "20240401040500", "headline": "Vertex announces acceptance of NDS for exagamglogene autotemcel", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240401043400", "headline": "Vertex's NDS for its sickle cell disease and thalassemia treatment accepted for priority review by Health Canada", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240401060000", "headline": "Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease", "summary": "BOSTON, April 01, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care. The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two v"}, {"date": "20240401062300", "headline": "Vertex moves kidney disease drug into late-stage testing", "summary": "The drug, inaxaplin, is an important pipeline prospect for Vertex, which is working to expand beyond the cystic fibrosis medicines that made its name."}, {"date": "20240401070000", "headline": "Missed the \"Magnificent Seven\"? Try Buying These 3 Forever Stocks Instead", "summary": "All three companies have very long runways for growth ahead."}, {"date": "20240401090000", "headline": "Vertex Announces New Drug Submission for Exagamglogene Autotemcel (exa-cel) Has Been Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia", "summary": "Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its New Drug Submission (NDS) for exagamglogene autotemcel (exa-cel) has been accepted for Priority Review by Health Canada for the treatment of patients aged 12 years and older with sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) and for the treatment of patients aged 12 years and older with transfusion-dependent beta thalassemia (TDT)."}, {"date": "20240401155020", "headline": "Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know", "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $420.48, denoting a +0.59% change from the preceding trading day."}, {"date": "20240401223200", "headline": "Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), Vertex Pharmaceuticals (VRTX) and Veeva Systems (VEEV)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240402002100", "headline": "Analysts Offer Insights on Healthcare Companies: Smith & Nephew Snats (SNN), Ocuphire Pharma (OCUP) and Vertex Pharmaceuticals (VRTX)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240402002600", "headline": "Truist Financial Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240402032134", "headline": "Vertex Advances Inaxaplin into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease", "summary": "BOSTON - Vertex Pharmaceuticals Incorporated today announced that inaxaplin has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease ,..."}, {"date": "20240402043900", "headline": "Biotech Roundtable: Who will bring the next CRISPR drug to market?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240402092600", "headline": "Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development", "summary": "Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease."}, {"date": "20240403022500", "headline": "Truist pharmaceuticals analyst holds an analyst/industry conference call", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240403080002", "headline": "Vertex Is Worth Your Attention", "summary": "The company's promising pipeline holds several catalysts in reserve outperformance in 2024"}, {"date": "20240403170051", "headline": "Insider Sell: SVP & Chief Accounting Officer Kristen Ambrose Sells Shares of Vertex ...", "summary": "On April 2, 2024, Kristen Ambrose, the Senior Vice President & Chief Accounting Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 240 shares of the company."}, {"date": "20240403180226", "headline": "3 Underappreciated Healthcare Stocks to Buy Now: April 2024", "summary": "The healthcare sector is a constant source of innovation and growth. Yet, even amidst the spotlight on industry giants, a realm of underappreciated gems still exists. The top underappreciated healthcare stocks to buy offer a unique opportunity for savvy investors to capitalize on burgeoning trends and new drug discoveries. While some players may operate in niche segments, their potential for substantial returns makes them compelling growth prospects. As investors continue to seek opportunities f"}, {"date": "20240404040700", "headline": "VRTX May 24th Options Begin Trading", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240404214500", "headline": "Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240405073000", "headline": "Got $1,000? 2 Bulletproof Stocks to Buy in 2024 and Hold for the Long Haul", "summary": "These businesses are booming."}, {"date": "20240408030700", "headline": "RBC says pain opinion leader 'notably negative' on Vertex's VX-548", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240408033100", "headline": "Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409000600", "headline": "3 High-Growth Biotech Stocks Investors Shouldn\u2019t Sleep On in April", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409020000", "headline": "Vortex Energy Announces Drilling Update and $115,500 Grant Award At The Robinsons River Salt Project", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409021700", "headline": "Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409043500", "headline": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.", "summary": "These companies are close to launching new products that could supercharge revenue."}, {"date": "20240409053717", "headline": "11 Best Biotech ETFs To Buy", "summary": "In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus [\u2026]"}, {"date": "20240409054000", "headline": "Vortex Energy Gears Up for Pivotal Drilling Phase", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409080000", "headline": "Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics", "summary": "These rising drugmakers have serious arguments in their favor."}, {"date": "20240409080700", "headline": "This Growth Stock Is One Step Closer to Launching a New Blockbuster: Time to Buy?", "summary": "This innovative machine rolls on."}, {"date": "20240409140500", "headline": "Vertex to Announce First Quarter 2024 Financial Results on May 6", "summary": "BOSTON, April 09, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2024 financial results on Monday, May 6, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the \"Vertex Pharmaceuticals First Quarter 2024 Earnings Call.\""}, {"date": "20240409210200", "headline": "Vertex to acquire Alpine Immune Sciences for $65 per share", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240409223600", "headline": "Fly Intel: After-Hours Movers", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410021100", "headline": "Analysts\u2019 Top Healthcare Picks: Humacyte (HUMA), Janux Therapeutics Inc (JANX)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410072700", "headline": "This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?", "summary": "GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema"}, {"date": "20240410101609", "headline": "Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln", "summary": "Vertex Pharmaceuticalswill acquire therapy developer Alpine Immune Sciencesfor $65 per share, or about $4.9 billion in cash, the companiessaid on Wednesday. With the acquisition,..."}, {"date": "20240410103400", "headline": "Vertex Pharma agrees to buy Alpine Immune Sciences for USD4.9 billion", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410112532", "headline": "Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update", "summary": "By Ben Glickman Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue to..."}, {"date": "20240410113400", "headline": "Vertex to buy kidney disease drugmaker Alpine for $4.9B", "summary": "The deal, which company CEO Reshma Kewalramani described as \u201cjust the right fit,\u201d is the largest acquistion in Vertex\u2019s 35-year history."}, {"date": "20240410140100", "headline": "Vertex Enters Into Agreement to Acquire Alpine Immune Sciences", "summary": "BOSTON & SEATTLE, April 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Director"}, {"date": "20240410141609", "headline": "UPDATE 3-Vertex Pharma bets on kidney disease treatment with $4.9 bln Alpine Immune deal", "summary": "Vertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to the biotech firm's treatment for an autoimmune disease of the kidney, the companies said on Wednesday.  The deal values each share of Alpine at $65, representing a premium of about 67% to the stock's close on Tuesday, a day before Bloomberg News reported that the company was considering options after attracting takeover interest.  Shares of Alpine were up 36% in extended trading, while Vertex Pharma was down about 1%."}, {"date": "20240410141933", "headline": "Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal", "summary": "The deal values each share of Alpine at $65, representing a premium of about 67% to the stock's close on Tuesday, a day before Bloomberg News reported that the company was considering options after attracting takeover interest.  Shares of Alpine were up 36% in extended trading, while Vertex Pharma was down about 1%.  Vertex currently has approval from the U.S. Food and Drug Administration for the treatments of cystic fibrosis \u2014 a rare genetic disorder that affects mostly the lungs \u2014 and two types of blood disorders, namely sickle cell disease and transfusion-dependent beta thalassemia."}, {"date": "20240410151445", "headline": "Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal", "summary": "Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed almost 21% on rumors of the deal."}, {"date": "20240410154700", "headline": "Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion", "summary": "The deal would give the pharmaceutical giant access to Alpine\u2019s potential treatment for chronic kidney disease."}, {"date": "20240410160020", "headline": "Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note", "summary": "Vertex Pharmaceuticals (VRTX) reachead $397.58 at the closing of the latest trading day, reflecting a -1.71% change compared to its last close."}, {"date": "20240410183000", "headline": "GLOBAL BRIEFING: Chinese inflation cooler than expected in March", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410191700", "headline": "Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410195300", "headline": "Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410205300", "headline": "Stock market today: Wall Street rebounds following its slide as Big Tech takes the reins again", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410212400", "headline": "What You Missed On Wall Street On Thursday", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410214800", "headline": "M&A: Vertex Bolsters Drug Pipeline with Alpine Immune Deal", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410215300", "headline": "M&A: Vertex Bolsters its Drug Portfolio with Alpine Immune Deal", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410215600", "headline": "M&A: Vertex Bolsters its Drug Portfolio with Alpine Deal", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410221100", "headline": "Alpine Immune downgraded to Sector Perform from Outperform at RBC Capital", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410221700", "headline": "Buy Rating Affirmed for Vertex Pharmaceuticals Post Alpine Therapeutics Acquisition", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410222300", "headline": "Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Amylyx Pharmaceuticals Inc (AMLX)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410225800", "headline": "Strategic Acquisition and Pipeline Expansion Justify Buy Rating for Vertex Pharmaceuticals", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410232300", "headline": "Drugmakers look to alternative suppliers after draft U.S. legislation, FT says", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410232700", "headline": "Vertex Pharmaceuticals just upgraded at Evercore ISI, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410233500", "headline": "Evercore expects Vera Therapeutics to trade up on Alpine acquisition news", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410233800", "headline": "Evercore ISI upgrades Vertex Pharmaceuticals (VRTX) to a Buy", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240410235700", "headline": "Buy Rating Justified by Vertex Pharmaceuticals\u2019 Strategic Acquisitions and Promising Drug Pipeline", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411001722", "headline": "Futures slip as rate-cut hopes ebb", "summary": "U.S. stock index futures dipped onThursday as Treasury yields remained elevated a day after a hotinflation reading triggered a bruising Wall Street sell-off,diminishing hopes of a June rate cut by..."}, {"date": "20240411001800", "headline": "Futures Dip as Treasury Yields Stay High, Fed Rate Cut Hopes Diminish", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411002600", "headline": "Stifel Nicolaus Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411003400", "headline": "Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411004900", "headline": "Alpine Immune Sciences just downgraded at Leerink, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411014100", "headline": "Vertex Pharma upgraded at Evercore on Alpine Immune deal", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411014300", "headline": "Vertex Pharmaceuticals price target raised by $5 at H.C. Wainwright, here's why", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411024100", "headline": "DoorDash upgraded, Airbnb downgraded: Wall Street's top analyst calls", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411034022", "headline": "Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'", "summary": "Vertex Pharmaceuticals (VRTX) to acquire Alpine Immune Sciences (ALPN) for $4.9b in cash. Check out why I think this deal may be a little overpriced."}, {"date": "20240411034400", "headline": "Apple Spyware Warning: What to Know About \u2018Mercenary Spyware Attack\u2019 Alerts", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411035000", "headline": "Analyst thinks this drugmaker could be next after Alpine's $4.9B acquisition", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411040900", "headline": "Raymond James Just Raised Its Price Target on Nvidia (NVDA) Stock", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411041722", "headline": "US STOCKS-Futures slip as rate-cut hopes ebb", "summary": "U.S. stock index futures dipped on Thursday as Treasury yields remained elevated a day after a hot inflation reading triggered a bruising Wall Street sell-off, diminishing hopes of a June rate cut by the Federal Reserve.  Wall Street sold off sharply in the last session after data showed U.S. consumer prices increased more than expected in March, leading financial markets to deduce that the central bank might delay cutting interest rates until September this year.  Further fueling concerns, minutes of the central bank's March meeting showed officials were worried that progress on inflation could have stalled and a longer period of tight monetary policy might be needed to tame the pace of price increases."}, {"date": "20240411050300", "headline": "What You Missed On Wall Street This Morning", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411061400", "headline": "Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411062500", "headline": "Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411071500", "headline": "Vertex Pharmaceuticals: Buy, Sell, or Hold?", "summary": "The stock hasn't made for a great buy this year, but is Vertex worth investing in for the long run?"}, {"date": "20240411073926", "headline": "Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer", "summary": "(Bloomberg) -- Vertex Pharmaceuticals Inc. agreed to buy Alpine Immune Sciences Inc. for a total equity value of about $4.9 billion, adding the biotech company\u2019s immune treatments in its biggest acquisition ever.Most Read from BloombergUS Sees Imminent Missile Strike on Israel by Iran, ProxiesUS Slams Strikes on Russia Oil Refineries as Risk to Oil MarketsVietnam Tycoon Lan Sentenced to Death Over $12 Billion FraudRussia Destroys Largest Power Plant in Ukraine\u2019s Kyiv RegionChinese Cement Maker H"}, {"date": "20240411074743", "headline": "These Stocks Are Moving the Most Today", "summary": "Earnings at CarMax miss analysts\u2019 estimates, Alpine Immune Sciences is being acquired by Vertex Pharmaceuticals for $4.9 billion in cash, Robinhood stock is downgraded, and Nike receives an upgrade.Read ..."}, {"date": "20240411074756", "headline": "The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today", "summary": "Drug maker Alpine Immune Sciences (NASDAQ:ALPN) got a $4.9 billion buyout offer from Vertex Pharmaceuticals (NASDAQ:VRTX) after getting good news on a new drug. Povetacicept, an autoimmune drug, won a successful Phase 2 review from the Food and Drug Administration (FDA) for treating a rare kidney disease and will go into Phase 3 trial. Alpine stock rose 21% on April 10, and another 36% overnight, opening April 11 at $64.18 per share. InvestorPlace - Stock Market News, Stock Advice & Trading Tips"}, {"date": "20240411075833", "headline": "Stocks to Watch Thursday: Robinhood, Alpine Immune, Constellation Brands", "summary": "\u2197\ufe0f **Alpine Immune Sciences (ALPN)**: Biotech company **Vertex Pharmaceuticals (VRTX)** agreed to buy Alpine for $4.9 billion, to bolster its kidney-disease portfolio. The target company's shares soared over 36%, extending Wednesday's gains."}, {"date": "20240411082742", "headline": "Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised", "summary": "The Dow fell after initially rising on the PPI inflation report on the stock market today. Analysts hiked Microsoft and Nvidia price targets."}, {"date": "20240411083645", "headline": "Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It", "summary": "Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed almost 21% on rumors of the deal."}, {"date": "20240411090300", "headline": "Vertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street  Says.", "summary": "Vertex Pharmaceuticals  is taking a big swing to secure its own second act: Late Wednesday, it announced a $4.9 billion deal to buy  Alpine Immune Sciences  which is developing a drug to treat a rare kidney disease.  Vertex said it would pay $65 per share for Alpine, a 38.2% premium over the stock\u2019s Wednesday closing price of $47.04.  Shares of Alpine were trading at $64.19 early Thursday, while Vertex shares were up 1.2%."}, {"date": "20240411092348", "headline": "What Vertex Pharmaceuticals Is Getting With Acquisition Of Alpine Immune Sciences", "summary": "Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept. Read more on VRTX and ALPN stocks here."}, {"date": "20240411101800", "headline": "NEW YORK MARKET CLOSE: Soft PPI spurs tech stocks ahead of earnings", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240411104836", "headline": "Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement", "summary": "Vertex is acquiring Alpine Immune Sciences for $4.9 billion in cash to obtain the use of povetacicept for IgAN. Check out more on VRTX and ALPN stock here."}, {"date": "20240411142902", "headline": "Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal", "summary": "Vertex Pharmaceuticals (VRTX) is set to acquire Alpine Immune Sciences (APLN) for $4.9 billion in cash, gaining access to Alpine's treatments for kidney disease. The deal from Vertex values Alpine's stock at $65 a share, which is a nearly 67% premium from the stock's close on Tuesday. Yahoo Finance Anchors Josh Lipton and Julie Hyman discuss the trend of \"pipeline in a product\" deals. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino"}, {"date": "20240411230854", "headline": "Vertex Pharmaceuticals: Alpine Accelerates Aspiration To Become Biotech Powerhouse", "summary": ""}, {"date": "20240412012000", "headline": "ClearBridge Aggressive Growth Strategy Q1 2024 Portfolio Manager Commentary", "summary": "2023's positive momentum extended into Q1 as increased likelihood of an economic soft landing combined with a relatively favorable monetary backdrop sent stocks broadly higher."}, {"date": "20240412035600", "headline": "Vertex Pharmaceuticals\u2019 Hold Rating: Balancing Cystic Fibrosis Success with Uncertain Growth from New Acquisition", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412040900", "headline": "Biotech Alert: Searches spiking for these stocks today", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412060400", "headline": "The Analyst Landscape: 16 Takes On Vertex Pharmaceuticals", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412063700", "headline": "Analyst Maintains \u2018Sell\u2019 Rating on Vertex Pharmaceuticals Amid Skepticism Over Alpine Acquisition and Early-Stage Data", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412064100", "headline": "Buy Rating Affirmed: Vertex Pharmaceuticals\u2019 Strategic Acquisition and Market Positioning Promise Growth", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412064100", "headline": "Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240412103600", "headline": "Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex", "summary": "Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024."}, {"date": "20240413032900", "headline": "Could This Stock Be the Next Biotech Buyout?", "summary": "Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease."}, {"date": "20240413064700", "headline": "3 Magnificent Stocks That Could Double or More by 2030", "summary": "There's no guarantee these stocks will double by 2030, but their growth prospects look great."}, {"date": "20240414190600", "headline": "Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240414215300", "headline": "TD Cowen says sickle cell therapies may get higher CMS payments", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415004100", "headline": "Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Vertex Pharmaceuticals (VRTX) and Amgen (AMGN)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240415070410", "headline": "Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know", "summary": "Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects."}, {"date": "20240415071500", "headline": "Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock", "summary": "Vertex just laid claim to an asset that might be very valuable."}, {"date": "20240415100041", "headline": "Vertex Pharma scientist talks about the long road to developing non-addictive painkillers", "summary": "For decades, patients seeking medication for pain have had two choices: over-the-counter drugs like aspirin or powerful prescription opioids like oxycodone.  Opioid prescriptions have plummeted over the last decade as doctors have become more attuned to the risks of addiction and misuse during the country\u2019s ongoing drug epidemic.  Vertex Pharmaceuticals recently reported positive results for a non-opioid painkiller, one of several medications the Boston-based drugmaker has been developing for various forms of pain."}, {"date": "20240416020000", "headline": "Vortex Energy Corp. Sends Core Samples from the Robinsons River Salt Project to the University of Alberta", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416050600", "headline": "If You Invested $1000 In This Stock 10 Years Ago, You Would Have $6,000 Today", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416053800", "headline": "Vortex Energy Advances Salt Project Analysis", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240416214800", "headline": "Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240417234600", "headline": "Buy Rating on Vertex Pharmaceuticals Fueled by Promising IgAN Therapy and Strategic Acquisition", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418013000", "headline": "Vertex Pharmaceuticals announces advancements in suzetrigine pain program", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418015000", "headline": "Tesla To $123? Here Are 10 Top Analyst Forecasts For Thursday", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418015300", "headline": "Vertex starts rolling FDA submission for non-opioid pain therapy", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418023800", "headline": "Vertex\u2019s stock climbs as non-opioid pain treatment advances", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418050000", "headline": "Vertex begins bid for US approval of non-opioid painkiller", "summary": "The biotech has begun a rolling submission of a closely watched drug that\u2019s important to its future, but faces questions of sales potential."}, {"date": "20240418051500", "headline": "Guggenheim Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240418060000", "headline": "Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain", "summary": "BOSTON, April 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548)."}, {"date": "20240418063000", "headline": "Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?", "summary": "The biotech just added another potential growth driver to its pipeline."}, {"date": "20240419003200", "headline": "CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240419023000", "headline": "Is Vertex Pharmaceuticals Stock a Millionaire Maker?", "summary": "Does this pharma stock have the potential to turn a $25,000 investment into seven figures or more?"}, {"date": "20240419032331", "headline": "Vertex Announces Advancements of Suzetrigine in Acute and Neuropathic Pain", "summary": "BOSTON - Vertex Pharmaceuticals Incorporated today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and..."}, {"date": "20240419095700", "headline": "Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug", "summary": "Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024."}, {"date": "20240419155018", "headline": "Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know", "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $394.28, indicating a +0.2% shift from the previous trading day."}, {"date": "20240420041500", "headline": "3 Biotech Stocks Set to Double by 2028", "summary": "Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies possesses the potential to deliver substantial returns in the coming years. It is no surprise that investors continue to turn to this sector as advancements in technology strengthen its growth prospects. From revolutionary gene therapies to cancer research, the possibilities are endless. Furthermore,"}, {"date": "20240420044800", "headline": "3 Relatively Safe Growth Stocks You Can Buy and Hold", "summary": "Low risk and high-reward potential? These stocks could offer both."}, {"date": "20240420060300", "headline": "THQ: Collecting A High Yield From Increased Medical Spending", "summary": "abrdn Healthcare Opportunities Fund (THQ) offers a high dividend yield and exposure to diverse healthcare subsectors, outperforming peers. Explore more here."}, {"date": "20240420074500", "headline": "2 Everlasting Big Pharma Stocks to Buy Today and Hold Forever", "summary": "These stocks probably won't be getting much cheaper."}, {"date": "20240422013200", "headline": "Vertex Pharmaceuticals (VRTX) Gets a Buy from Piper Sandler", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422035200", "headline": "Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now", "summary": "These stocks could be near major inflection points."}, {"date": "20240422051655", "headline": "If You'd Invested $10,000 in Vertex Pharmaceuticals 5 Years Ago, Here's How Much You'd Have Today", "summary": "Could Vertex's growth story continue?"}, {"date": "20240422061700", "headline": "Buy Rating on Vertex Pharmaceuticals: Risinger\u2019s Confidence in VX-548\u2019s Billion-Dollar Potential and FDA Progress", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422070300", "headline": "Making Sense of Amazon CEO Andy Jassy's Latest Letter", "summary": "And that's just part of the interesting news for investors to dig into."}, {"date": "20240422091059", "headline": "10 Best Performing Biotech ETFs in 2024", "summary": "In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for [\u2026]"}, {"date": "20240422204200", "headline": "Vertex obtains licence to TreeFrog's C-Stem to optimise own production", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422223400", "headline": "Vertex Pharmaceuticals, TreeFrog Therapeutics announce licensing agreement", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240422224500", "headline": "VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES", "summary": "Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-StemTM, to optimize production of Vertex's cell therapies for type 1 diabetes (T1D). TreeFrog and Vertex will collaborate to scale-up TreeFrog's process to produce and amplify cells for Vertex's T1D therapies."}, {"date": "20240423000116", "headline": "Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis", "summary": "Arcturus Therapeutics is on the verge of obtaining regulatory approvals for two gene therapies targeting rare diseases. See why ARCT stock is a Buy."}, {"date": "20240423021800", "headline": "Vertex in-licenses cell therapy technology for diabetes candidates", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240423033000", "headline": "Baron Health Care Fund Q1 2024 Shareholder Letter", "summary": "In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared with the 8.52% gain for the Russell 3000 Health Care Index and the 10.56% gain for the S&P 500 Index."}, {"date": "20240423033700", "headline": "Edgewise gets EU orphan drug status for muscular dystrophy drug", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240423035911", "headline": "Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics", "summary": "By Colin Kellaher Vertex Pharmaceuticals has struck an exclusive licensing agreement with privately held TreeFrog Therapeutics in a bid to bolster production of its cell therapies for type-1..."}, {"date": "20240423040500", "headline": "Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?", "summary": "Vertex is broadening its portfolio."}, {"date": "20240423060900", "headline": "Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies", "summary": "Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies."}, {"date": "20240423061900", "headline": "Health Care Roundup: Market Talk", "summary": "0710 GMT \u2013  Novartis  raised its outlook after first-quarter results beat  Barclays  and market expectations on a stronger-than-expected business performance and higher spending, Barclays analysts say in a note.  0652 GMT \u2013 Novartis beat expectations for first-quarter sales and earnings and raised its 2024 outlook for both metrics by a wider margin than expected, which could trigger increases to consensus expectations, Jefferies analysts say in a research note.  The Swiss pharmaceutical giant reported quarterly sales of $11.83 billion and a core operating profit of $4.54 billion, beating Jefferies\u2019s forecasts of $11.46 billion and $4.46 billion, respectively, the analysts say."}, {"date": "20240424003100", "headline": "Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240424035000", "headline": "Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.", "summary": "Good news could be just around the corner for two drugmakers not named Novo Nordisk."}, {"date": "20240424064009", "headline": "Crispr Therapeutics: Now Is The Time To Buy", "summary": "Despite recent FDA approvals for gene editing technology, CRISPR Therapeutics' stock declined. Click here to read an analysis of CRSP stock now."}, {"date": "20240424193500", "headline": "(VRTX) - Analyzing Vertex Pharmaceuticals's Short Interest", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425024100", "headline": "Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapies", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240425050000", "headline": "Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth", "summary": "Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.  Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver.  CRISPR, discovered by Jennifer Doudna and CRISPR Therapeutics co-founder Emmanuelle Charpentier, uses molecular \"scissors\" to trim faulty parts of genes that can then be disabled or replaced with new strands of normal DNA."}, {"date": "20240425074500", "headline": "2 Fantastic Growth Stocks to Buy Right Now", "summary": "Don't overlook these high-growth businesses."}, {"date": "20240425155019", "headline": "Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know", "summary": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $397.70, moving -0.76% from the previous trading session."}, {"date": "20240425193800", "headline": "$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426040300", "headline": "Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426044700", "headline": "Vertex announces European Commission approval for KALYDECO", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426051600", "headline": "Interesting VRTX Put And Call Options For June 7th", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240426062500", "headline": "The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals", "summary": "Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog."}, {"date": "20240426094300", "headline": "Vertex Announces European Commission Approval for KALYDECO\u00ae to Treat Infants With Cystic Fibrosis Ages 1 Month and Older", "summary": "LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO\u00ae (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R."}, {"date": "20240426102238", "headline": "Pioneer Institute study finds IRA discourages non-opioid drug innovation", "summary": "The IRA adds another hurdle to an already challenging research landscape, according to a study from the Pioneer Institute."}, {"date": "20240427035000", "headline": "Want $1 Million in Retirement? 3 Stocks to Buy Now And Hold for Decades.", "summary": "These three should have a lot of room to run."}, {"date": "20240428060400", "headline": "J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240428064500", "headline": "2 Top Growth Stocks to Buy Right Now and Hold Forever", "summary": "These healthcare stocks can provide enviable long-term portfolio growth."}, {"date": "20240429020000", "headline": "Vortex Energy\u2019s Collaboration with the University of Alberta Receives Alberta Innovates Funding", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429024200", "headline": "Analysts Offer Insights on Healthcare Companies: Accolade (ACCD), Vertex Pharmaceuticals (VRTX) and Zimmer Biomet Holdings (ZBH)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429050800", "headline": "Vortex Energy Spearheads Innovative Hydrogen Storage Trial", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240429080031", "headline": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?", "summary": "Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations."}, {"date": "20240430033600", "headline": "Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?", "summary": "Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio."}, {"date": "20240430072504", "headline": "Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics", "summary": "CRISPR Therapeutics'\u00c2\u00a0Casgevy could generate significant shareholder value if proven to be successful. Learn why I am highly bullish on CRSP stock."}, {"date": "20240501024900", "headline": "Global company events calendar", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240501070012", "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It", "summary": "Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock."}, {"date": "20240501080133", "headline": "Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know", "summary": "Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations."}, {"date": "20240502051500", "headline": "3 Biotech Stocks to Buy and Hold Through 2030 and Beyond", "summary": "It pays to develop novel medicines for life-threatening illnesses."}, {"date": "20240502155009", "headline": "Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know", "summary": "The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $400.16, representing a -0.49% change from its previous close."}, {"date": "20240502192200", "headline": "Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street\u2019s Radar", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502200000", "headline": "Catalyst Watch: Disney earnings, Apple iPad event and Fed speakers back on the circuit", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240502232000", "headline": "Shhh! 3 Secret Pharma Stocks Flying Below Wall Street\u2019s Radar", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503015100", "headline": "3 Growth Stocks You\u2019ll Kick Yourself for Not Buying Today", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503041700", "headline": "June 14th Options Now Available For Vertex Pharmaceuticals (VRTX)", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240503053000", "headline": "Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)", "summary": "Crispr Therapeutics AG stock is in a bear market as FOMO fades, but the growing portfolio and improving safety profile spells opportunity. Read more here."}, {"date": "20240503170107", "headline": "Insider Sale at Vertex Pharmaceuticals Inc (VRTX): Director Sangeeta Bhatia Sells Shares", "summary": "On May 2, 2024, Director Sangeeta Bhatia sold 467 shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) as reported in a recent SEC Filing."}, {"date": "20240504050200", "headline": "3 Biotech Stocks With the Potential to Make You an Overnight Millionaire", "summary": "Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results."}, {"date": "20240504053818", "headline": "23 Most Profitable Stocks of the Last 12 Months", "summary": "In this article, we discuss the 23 most profitable stocks of the last 12 months. If you want to skip our detailed analysis of these stocks, go directly to 5 Most Profitable Stocks of the Last 12 Months. The United States stock market has come a long way since the turn of the millennium more [\u2026]"}]}